Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 amp |
| Therapy | Pembrolizumab |
| Indication/Tumor Type | carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 amp | carcinoma | sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with cancer of unknown primary harboring CD274 amplification and overexpression, and a hypermutated genome was sensitive to Keytruda (pembrolizumab), demonstrating tumor regression after two months of treatment and a near complete remission after six months of treatment (PMID: 27900363). | 27900363 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27900363) | Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. | Full reference... |